Literature DB >> 7003784

Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease.

B J Pardy, J D Lewis, H H Eastcott.   

Abstract

Severe extremity ischemia frequently cannot be relieved by surgical means and failure of current drug therapy may then result in prolonged disability or amputation. Prostaglandins E1 (PGE1) and I2 (prostacyclin, PGI2) are potent vasodilators and inhibitors of platelet aggregation which have been reported to be of value in the treatment of peripheral ischemia. Nineteen patents with severe extremity ischemia and one with vasculitic leg ulceration were treated on 25 occasions by intravascular infusion of PGE1 or PGI2 for 72 to 96 hours. Causes of ischemia were arteriosclerosis, Raynaud's phenomenon (secondary), Buerger's disease, and "trash" foot. Prolonged pain relief and promotion of tissue healing occurred mainly in patents with patent proximal axial arteries. Patency of the superficial femoral artery was associated with a good clinical response in eight of nine cases of foot ischemia, and mean hallux temperature rose 4.6 +/- 2.5 degrees C. In contrast, occlusion of the artery was associated with failure in eight of nine cases, and hallux temperature rose 0.6 degrees +/- 1.3 degrees C. PGE1 or PGI2 administered intravenously may be the treatment of choice for severe ischemia in distal arteriopathy, although the exact mechanisms by which these prostaglandins act are far from clear.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7003784

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

Review 1.  Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

Review 2.  Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Postgrad Med J       Date:  1983-12       Impact factor: 2.401

3.  Prostaglandin therapy in severe limb ischemia.

Authors:  B J Pardy; H H Eastcott
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

Review 4.  Prostaglandins and the cardiovascular system.

Authors:  J R Vane
Journal:  Br Heart J       Date:  1983-05

5.  Prostaglandins in vascular disease.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-25

6.  Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.

Authors:  M F Martin; J E Tooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11

Review 7.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

8.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

9.  Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

Authors:  H Sinzinger; J O'Grady; P Fitscha
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

10.  Influence of parenteral prostaglandin E1 on lung mechanics in normal man.

Authors:  N Naeije; M Bracamonte; R Sergijsels
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.